New Prospective for the Management of Low-Risk Pulmonary Embolism: Prognostic Assessment, Early Discharge, and Single-Drug Therapy with New Oral Anticoagulants
Table 3
Published phase III trials on acute treatment of pulmonary embolism.
Study
Patients
Intervention
Comparison
Primary outcome (recurrent VTE)
RECOVER
Acute symptomatic VTE, DVT, and/or PE, who were initially given parenteral anticoagulation therapy
Dabigatran etexilate (150 mg twice daily)
Dose-adjusted warfarin (INR 2.0 to 3.0)
Dabigatran: 30 (2.4%) Warfarin 27 (2.1%)
RECOVER II
Acute symptomatic VTE, DVT, and/or PE, who were initially given parenteral anticoagulation therapy
Dabigatran etexilate (150 mg twice daily)
Dose-adjusted warfarin (INR 2.0 to 3.0)
Dabigatran: 30 (2.4%) Warfarin 28 (2.2%)
EINSTEIN-PE
Acute symptomatic PE
Rivaroxaban (15 mg bid for the first 3 weeks followed by 20 mg od)
LMWH and dose-adjusted VKA (INR 2.0 to 3.0)
Rivaroxaban: 50 (2.1%) LMWH/VKA: 44 (1.8%)
CASSIOPEA
Symptomatic PE with or without symptomatic DVT, who were initially given parenteral anticoagulation therapy
Idrabiotaparinux 3.0 mg s.c. once weekly
Dose-adjusted warfarin (INR 2.0 to 3.0)
Idrabiotaparinux: 34 (2.1%) Warfarin: 43 (2.7%)
VTE: venous thromboembolism; DVT: deep venous thrombosis; PE: pulmonary embolism; LMWH: low-molecular-weight heparin; VKA: vitamin K antagonist.